欧洲和中国心脏调查预后和潜在的治疗意义-英文课件演示幻灯片.pptVIP

10th South China International Congress of Cardiology ACE trial symposium Prognostic and potential therapeutic implications of the European and China Heart surveys;Implications of the European and China Heart Surveys;Implications of the European and China Heart Surveys; GAMI1 n=164;DM;Mortality in CVD Relation to fasting and postprandial glycemia in patients without diabetes;Guideline recommendations; Diabetes and prediabetes is more common among patients with coronary artery disease than imagined Newly detected dysglycemia relates to impaired prognosis;RR 1995-1998 =1.42 RR 1999-2002 =1.31;OGTT at discharge (n= 168);;Multifactorial intervention in type 2 diabetes The Steno 2 study - 8 year follow up ;Project team every 3 months Strict therapeutic targets Behavioural modification fat 30% (satur 10%) exercise 30 min x3-5/week smoking cess courses Vitamin supplementation Stepwise introduced drugs Hypoglycemic regimen according to strict rules;Multifactorial intervention in type 2 diabetes The Steno 2 study – 8 years of follow up;;Impact of intensive therapy on OR 95% CI ARR p-value All-cause mortality 0.54 0.32-0.89 20% 0.015 Cardiovascular mortality 0.43 0.19-0.94 13% 0.036 Major cardiovascular events 0.41 0.25-0.63 29% 0.001;Euro Heart Survey diabetes and the heart Impact of Evidence Based Medicine on 1-year prognosis;p0.001;Euro Heart Survey diabetes and the heart Impact of Evidence Based Medicine (EBM) on 1-year CVE;;;Euro Heart Survey diabetes and the heart Number needed to treat (NNT) with EBM and Revascularisation;Guideline recommendations;Implications of the European and China Heart Surveys;with CAD;Glycemic control Evidence for impact on cardiovascular events;Glycemic control Incidence of composite cardiovascular events in the STOP-NIDDM trial;4961;Prescribed glucose lowering drugs 77 (17%) ;0,90;Euro Heart Survey diabetes and the heart HR for the impact of GLD on 1-year CV –events in newly detected DM;Guideline recommendations;1